Excitement Builds for Tremfya Among US Gastroenterologists as the FDA Approves its Expansion into Crohn’s Disease, Suggesting the Brand May Impact Competitor Skyrizi’s Growth
Gastroenterologists are enthusiastic about Tremfya’s subcutaneous induction option in Crohn’s disease, a key potential brand differentiator, according to Spherix Global